Gregory Cogert, MD
Clinical Cardiac Electrophysiology · Santa Barbara, CANPI 1063541043
Payments from drug & device makers
Across 677 payments — averaging $59.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Abbott$11K
- Biosense Webster, Inc.$7K
- Boston Scientific$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$260
- Pfizer$194
- plus $1K from 19 others
Across 32 payments — averaging $4399.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$141K
What the payments were for
- Consulting fees$9,32530%
- Speaking & faculty fees$4,40014%
- Travel & lodging$6,56321%
- Food & beverage$11,04935%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 240 | $19,747 |
| Abbott | 24 | $10,634 |
| Biosense Webster, Inc. | 253 | $6,580 |
| Boston Scientific | 65 | $1,158 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $260 |
| Pfizer | 9 | $194 |
| Lundbeck LLC | 8 | $175 |
| Sanofi-aventis U.S. LLC | 8 | $170 |
| Johnson & Johnson | 13 | $159 |
| Novartis | 8 | $125 |
| E.r. Squibb & Sons, L.L.C. | 6 | $107 |
| Cordis US CORP. | 1 | $96 |
| Alnylam Pharmaceuticals Inc. | 4 | $91 |
| Boehringer Ingelheim | 3 | $75 |
| Regeneron Healthcare Solutions, Inc. | 5 | $74 |
| AstraZeneca | 4 | $69 |
| Cardiva Medical, Inc. | 3 | $58 |
| Shockwave Medical, Inc | 1 | $57 |
| Irhythm Technologies, Inc. | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $36 |
| Portola Pharmaceuticals, LLC | 1 | $26 |
| Edwards Lifesciences | 1 | $21 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Amgen | 1 | $17 |
| Atricure, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arctic Front$2,400
- AVEIR$1,537
- SPHERE-9$1,268
- Carto 3$673
- PulseSelect$474
- AFFERA MAPPING SYSTEM$405
- ENSITE PRECISION$169
- SelectSecure$151
- GENERAL - THERAPIES$129
- Watchman$127
- QDOT MICRO Catheter$126
- Claria MRI$118
- NUVISION ICE CATHETER$111
How this compares
$40,006 in reported general payments places this provider in the 50th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,041 | $1,226,385 |
| XareltoRivaroxaban | 259 | $305,840 |
| EntrestoSacubitril/Valsartan | 74 | $88,776 |
| FarxigaDapagliflozin Propanediol | 72 | $70,786 |
| Repatha SureclickEvolocumab | 47 | $38,458 |
| JardianceEmpagliflozin | 27 | $15,011 |
| Metoprolol Succinate | 654 | $11,875 |
| MultaqDronedarone Hcl | 12 | $10,963 |
| Droxidopa | 11 | $7,647 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 185 | $6,400 |
| Carvedilol | 435 | $4,717 |
| Flecainide Acetate | 92 | $4,658 |
| Rosuvastatin Calcium | 141 | $4,597 |
| Amiodarone Hcl | 223 | $4,399 |
| Dofetilide | 12 | $4,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $194 | $1,226,3851,041 claims |
| Johnson & JohnsonXarelto | $159 | $305,840259 claims |
| NovartisEntresto | $125 | $88,77674 claims |
| AstraZenecaFarxiga | $69 | $70,78672 claims |
| Boehringer IngelheimJardiance | $75 | $15,01127 claims |
| Sanofi-aventis U.S. LLCMultaq | $170 | $10,96312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in Santa Barbara
- Brett GidneySanta Barbara$885K
- David KrummenSan Diego$7.3M
- Jonathan DukesVentura$2.9M
- Shephal DoshiSanta Monica$2.9M
- Arash AryanaSacramento$2.4M
- Marco PerezStanford$2.1M
- Rahul DoshiLos Angeles$2M
- Mayer RashtianPasadena$1.8M
- Rajesh BankerNewport Beach$1.6M
- Edward GerstenfeldSan Francisco$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.